[Congressional Bills 114th Congress]
[From the U.S. Government Publishing Office]
[H.R. 2820 Reported in Senate (RS)]

<DOC>





                                                       Calendar No. 311
114th CONGRESS
  1st Session
                                H. R. 2820


_______________________________________________________________________


                   IN THE SENATE OF THE UNITED STATES

                           September 9, 2015

     Received; read twice and referred to the Committee on Health, 
                     Education, Labor, and Pensions

                            December 3, 2015

              Reported by Mr. Alexander, with an amendment
 [Strike out all after the enacting clause and insert the part printed 
                               in italic]

_______________________________________________________________________

                                 AN ACT


 
To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and 
                          for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

<DELETED>SECTION 1. SHORT TITLE.</DELETED>

<DELETED>    This Act may be cited as the ``Stem Cell Therapeutic and 
Research Reauthorization Act of 2015''.</DELETED>

<DELETED>SEC. 2. AMENDMENTS TO THE STEM CELL THERAPEUTIC AND RESEARCH 
              ACT OF 2005.</DELETED>

<DELETED>    (a) Cord Blood Inventory.--Section 2 of the Stem Cell 
Therapeutic and Research Act of 2005 (42 U.S.C. 274k note) is amended 
in subsection (h)--</DELETED>
        <DELETED>    (1) in paragraph (1)--</DELETED>
                <DELETED>    (A) by striking ``$23,000,000 for each of 
                fiscal years 2011 through 2014 and''; and</DELETED>
                <DELETED>    (B) by inserting before the period at the 
                end the following: ``and $23,000,000 for each of fiscal 
                years 2016 through 2020''; and</DELETED>
        <DELETED>    (2) in paragraph (2), by striking ``2011 through 
        2015'' and inserting ``2015 through 2020''.</DELETED>
<DELETED>    (b) National Program.--Section 379B of the Public Health 
Service Act (42 U.S.C. 274m) is amended by striking ``2011 through 
2014'' and inserting ``2016 through 2020''.</DELETED>

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Stem Cell Therapeutic and Research 
Reauthorization Act of 2015''.

SEC. 2. REAUTHORIZATION OF THE C.W. BILL YOUNG CELL TRANSPLANTATION 
              PROGRAM.

    (a) In General.--Section 379(d)(2)(B) of the Public Health Service 
Act (42 U.S.C. 274k(d)(2)(B)) is amended--
            (1) by striking ``remote collection'' and inserting 
        ``collection''; and
            (2) by inserting ``including remote collection,'' after 
        ``cord blood units,''.
    (b) Authorization of Appropriations.--Section 379B of the Public 
Health Service Act (42 U.S.C. 274m) is amended--
            (1) by striking ``$30,000,000 for each of fiscal years 2011 
        through 2014 and''; and
            (2) by inserting ``and $30,000,000 for each of fiscal years 
        2016 through 2020'' before the period at the end.
    (c) Secretary Review on State of Science.--The Secretary of Health 
and Human Services, in consultation with the Director of the National 
Institutes of Health, the Commissioner of the Food and Drug 
Administration, and the Administrator of the Health Resources and 
Services Administration, including the Advisory Council on Blood Stem 
Cell Transplantation established under section 379(a) of the Public 
Health Service Act (42 U.S.C. 274k(a)), and other stakeholders, where 
appropriate given relevant expertise, shall conduct a review of the 
state of the science of using adult stem cells and birthing tissues to 
develop new types of therapies for patients, for the purpose of 
considering the potential inclusion of such new types of therapies in 
the C.W. Bill Young Cell Transplantation Program (established under 
such section 379) in addition to the continuation of ongoing 
activities. Not later than June 30, 2019, the Secretary shall submit to 
the Committee on Health, Education, Labor, and Pensions of the Senate 
and the Committee on Energy and Commerce of the House of 
Representatives recommendations on the appropriateness of such new 
types of therapies for inclusion in the C.W. Bill Young Cell 
Transplantation Program.

SEC. 3. CORD BLOOD INVENTORY.

    Section 2 of the Stem Cell Therapeutic and Research Act of 2005 (42 
U.S.C. 274k note) is amended--
            (1) in subsection (a), by striking ``one-time'';
            (2) by striking subsection (c);
            (3) by redesignating subsections (d) through (h) as 
        subsections (c) through (g), respectively;
            (4) in subsection (d) (as so redesignated)--
                    (A) in paragraph (1), by striking ``paragraphs (2) 
                and (3)'' and inserting ``paragraphs (2), (3), and 
                (4)'';
                    (B) in paragraph (2)(B), by striking ``subsection 
                (d)'' and inserting ``subsection (c)''; and
                    (C) by adding at the end the following:
            ``(4) Consideration of best science.--The Secretary shall 
        take into consideration the best scientific information 
        available in order to maximize the number of cord blood units 
        available for transplant when entering into contracts under 
        this section, or when extending a period of funding under such 
        a contract under paragraph (2).
            ``(5) Consideration of banked units of cord blood.--In 
        extending contracts pursuant to paragraph (3), and determining 
        new allocation amounts for the next contract period or contract 
        extension for such cord blood bank, the Secretary shall take 
        into account the number of cord blood units banked in the 
        National Cord Blood Inventory by a cord blood bank during the 
        previous contract period, in addition to consideration of the 
        ability of such cord blood bank to increase the collection and 
        maintenance of additional, genetically diverse cord blood 
        units.'';
            (5) in subsection (f) (as so redesignated)--
                    (A) by striking paragraph (4); and
                    (B) by redesignating paragraphs (5) and (6) as 
                paragraphs (4) and (5), respectively; and
            (6) in subsection (g) (as so redesignated)--
                    (A) in paragraph (1)--
                            (i) by striking ``$23,000,000 for each of 
                        fiscal years 2011 through 2014 and''; and
                            (ii) by inserting ``and $23,000,000 for 
                        each of fiscal years 2016 through 2020'' before 
                        the period at the end; and
                    (B) by striking paragraph (2).

SEC. 4. DETERMINATION ON THE DEFINITION OF HUMAN ORGAN.

    Not later than one year after the date of enactment of this Act, 
the Secretary of Health and Human Services shall issue determinations 
with respect to the inclusion of peripheral blood stem cells and 
umbilical cord blood in the definition of human organ.
                                                       Calendar No. 311

114th CONGRESS

  1st Session

                               H. R. 2820

_______________________________________________________________________

                                 AN ACT

To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and 
                          for other purposes.

_______________________________________________________________________

                            December 3, 2015

                       Reported with an amendment